Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-07059-w
Abstract: This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting. We constructed a Markov model to project the lifetime direct… read more here.
Keywords: plus aspirin; cost; cardiovascular diseases; rivaroxaban plus ... See more keywords
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.
Sign Up to like & getrecommendations! Published in 2019 at "Thrombosis research"
DOI: 10.1016/j.thromres.2019.09.033
Abstract: This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been… read more here.
Keywords: rivaroxaban plus; pathway inhibition; dual pathway;